Category: Technology Licenses
Created On: 2022-04-28
Record Count: 16
- Bacterial Infection
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 341530
Inflammatory Bowel Disease (IBD) This is a general term for an autoimmune disease affecting the bowel, including CD and UC. CD affects the small and large intestine, while UC affects the large intestine. Both diseases involve inflammation of the intestinal wall, leading to pain, bleeding, and ultimately, in some cases, surgical removal of part of the bowel.
Crohnâ€™s disease (CD) An IBD involving inflammation of the small and large intestines, leading to pain, bleeding, and ultimately in some cases surgical removal of parts of the bowel.
Ulcerative colitis (UC) An IBD causing chronic inflammation of the lining of the colon and rectum (unlike CD with inflammation throughout the gastrointestinal tract).
Rheumatoid arthritis (RA) A chronic, systemic inflammatory disease that causes joint inflammation, and usually leads to cartilage destruction, bone erosion and disability.
Inflammatory diseases is a large, unrelated group of disorders associated with abnormalities in inflammation.
IPSCIO Record ID: 7344
RMS RPC1063 is a novel, oral, once daily, selective and potent S1P1R modulator. RMS is a chronic autoimmune disorder of the central nervous system (CNS), characterized by recurrent acute exacerbations (relapses) of neurological dysfunction followed by variable degrees of recovery with clinical stability between relapses (remission).
RPC1063 for the treatment of UC IBD is comprised of two chronic, autoimmune, GI inflammatory disorders UC and Crohn's Disease (CD). UC is a GI inflammatory disorder involving ulcers in the colon and is characterized by a chronic course of remissions and exacerbations. Patients suffer from a multitude of GI symptoms, including diarrhea, rectal bleeding and abdominal pain.
IPSCIO Record ID: 263902
The name of the product is SalofalkÂ® 500 mg, Granu-StixÂ®. Salofalk Granu-Stix delivers the therapeutically active antiinflammatory agent mesalamine (5-aminosalicylic acid or 5-ASA) to the distal ileum and colon by means of dual-release granules.
The patents include Pellet formulation for the treatment of the intestinal tract, and, Pellet-type formulation intended for treating the intestinal tract.
Ulcerative colitis (UC) is a disease that affects your large intestine, or colon. It causes irritation and swelling called inflammation. … UC is a type of inflammatory bowel disease, but it's different from other diseases with similar symptoms, like Crohn's disease or irritable bowel syndrome.
IPSCIO Record ID: 281500
Licensor discovers and develops small molecule medicines with novel modes of action, three of which show promising patient results and are currently in late-stage development in multiple diseases.
IPSCIO Record ID: 372413
Crohn's disease is a type of inflammatory bowel disease (IBD) that may affect any segment of the gastrointestinal tract from the mouth to the anus
IPSCIO Record ID: 372409
The following comprise PATENT RIGHTS
United States Patent Number 6,764,838
United States Patent Application Numbers 09/362,598; 10/715,659; 10/779,249
These patents claim methods of producing a pharmaceutical preparation comprising an helminthic parasite preparation, pharmaceutical compositions suitable for oral administration comprising an isolated and purified T.suis helminthic parasite preparation, and methods of treating inflammatory bowel disease, including Crohnâ€™s and UC, in an individual by the administration of a T. suis helminthic parasite preparation, respectively.
CNDO-201 is a biologic product candidate comprising TSO for the treatment of autoimmune diseases. We initially plan to investigate TSO for the treatment of Crohnâ€™s, UC and MS.
The use of helminths in the treatment of autoimmune disease is based on the belief that the immune systems of populations living in the relatively sterile environments found in developed countries with little or no exposure to parasites may develop in abnormal ways. This â€œhygiene hypothesisâ€ is based on epidemiologic findings of an inverse relationship between automimmune diseases and helminthic colonization. The incidence of IBD is highest in the developed world and in temperate climates, with positive correlations noted among persons of higher socioeconomic status and high levels of domestic hygiene experienced in childhood. Conversely, the incidence of IBD is rare in less developed countries and in persons with blue-collar jobs involving exposure to dirt and physical exercise.
In contrast to the epidemiologic findings of IBD, the prevalence of helminths is highest in warm climates and in populations characterized by crowding, poor sanitation, and impure food supply. Furthermore, the incidence of IBD has increased over the past several decades, while the prevalence of helminths in the United States and Europe has steadily declined during the same time period. These findings have led to the idea that eliminating intestinal helminths in the industrialized world has eliminated a natural T regulatory cell mechanism that prevents excessive T-cell activation such as occurs in IBD as well as in other immune-mediated diseases such as MS, asthma and allergies.
The immunologic basis for helminth therapy for IBD is derived from experimental animal and human data demonstrating that these organisms alter immune responses beyond those directed against the worms. In animal models, helminths blunt Th1 responses and promote Th2 responses associated with increased production of IL-4 and IL-3. Helminthic colonization in humans can result in diminished Th1 immune responses to challenges with unrelated antigens, as well as increased production of immunomodulatory molecules such as IL-10, transforming growth factor (TGF)-ÃŸ, and regulatory T-cells. Thus, genetically susceptible persons who are never exposed to helminths may lack a strong Th2 immune response and develop a poorly regulated and destructive intestinal Th1 response, leading to chronic colitis or ileitis.
IPSCIO Record ID: 210693
IPSCIO Record ID: 256198
– Develop, use, Commercialize, sell, offer for sale and import Product in the Licensee Territory, and,
– subject, as between Licensee and the Third Party, to the terms of the Third Party/Licensee Agreements, have Product made by Third Party, make and have made Product.
For the Cross-Licenses, Pre-Clinical Data and Clinical Data Sharing, Licensor grants
– an exclusive right and license, including the right to grant sublicenses, to and under Pre-Clinical Data and Clinical Data that is or becomes during the term of this Agreement owned or Controlled by Licensor to develop, use, import, sell, offer for sale, and Commercialize Product in the Field in the Licensee Territory, and subject, as between Licensee and the Third Party, to the terms of the Third Party/Licensee Agreements, have Product made by the Third Party, make and have made Product; and
– consents to Licensees right of reference and use of such Pre-Clinical Data and Clinical Data in connection with Regulatory Filings in the Licensee Territory.
Trichuris suis ova shall mean the ova or eggs of the Trichuris suis worm.
The U.S. Patent Application Nos. 12/594,074 and 12/993,517 are related to the Product.
Crohn's disease is an inflammatory bowel disease (IBD). It causes inflammation of your digestive tract, which can lead to abdominal pain, severe diarrhea, fatigue, weight loss and malnutrition.
Ulcerative colitis is a chronic disease of the large intestine, also known as the colon, in which the lining of the colon becomes inflamed and develops tiny open sores, or ulcers, that produce pus and mucous.
IPSCIO Record ID: 264191
ExtraCellular Matrix Hydrogel (ECMH), is a first-in-class, non-pharmacologic, non-surgical treatment option for patients suffering from Ulcerative Colitis.
Ulcerative colitis (UC) is a long-term condition that results in inflammation and ulcers of the colon and rectum. The primary symptoms of active disease are abdominal pain and diarrhea mixed with blood. Weight loss, fever, and anemia may also occur.
IPSCIO Record ID: 28777
ALX-0600 may also be useful in treating other gastrointestinal conditions characterized by malabsorption, altered absorptive capacity and inflammation or deterioration of the intestinal wall. Examples of these conditions include inflammatory bowel disease, like Crohnâ€™s Disease, and intestinal mucositis in cancer patients.
IPSCIO Record ID: 289928
ONS-3010 is a subcutaneous injectable mAb that binds to tumor necrosis factor alpha, or TNFa. TNFa belongs to a family of pro-inflammatory cytokines, or soluble protein mediators, that are key initiators of immune-mediated inflammation in many different diseases, such as rheumatoid arthritis, psoriatic arthritis, psoriasis, ankylosing spondylitis, Crohnâ€™s disease and ulcerative colitis. Several biologic agents, including Humira, have been developed to inhibit the inflammatory activity of TNFs in the context of these diseases and are collectively referred to as the anti-TNF class of therapeutics.
Humira, the reference product for ONS-3010, is a subcutaneous injectable mAb that binds to tumor necrosis factor alpha, or TNFa. TNFa belongs to a family of pro-inflammatory cytokines, or soluble protein mediators, that are key initiators of immune-mediated inflammation in many different diseases, such as rheumatoid arthritis, psoriatic arthritis, psoriasis, ankylosing spondylitis, Crohnâ€™s disease and ulcerative colitis. Several biologic agents, including Humira, have been developed to inhibit the inflammatory activity of TNFs in the context of these diseases and are collectively referred to as the anti-TNF class of therapeutics.
IPSCIO Record ID: 359530
IMU-935, is a highly potent and selective inverse agonist of a transcription factor called ROR?t with additional activity on DHODH. IMU-935 program is focused on an inverse agonist of ROR?t, an immune cell-specific isoform of retinoic acid receptor-related orphan nuclear receptor gamma (â€œROR?â€).
IPSCIO Record ID: 233469
Balsalazide means 5-[4(2-Carboxyethelcarbamoyl)-phenylazo] – salicylic acid disodium salt dihydrate.
Products means products incorporating Balsalazide, whether or not such products are covered by the Patent Rights, or any other material whose manufacture, use or sale by an unlicensed third party would constitute an infringement of any Valid Claim included within the Patent Rights.
First marketed product, Colazal, was the first new molecular entity approved in 10 years by the FDA for the treatment of mildly to moderately active ulcerative colitis and the first new oral therapy approved by the FDA for this indication in seven years. Ulcerative colitis is a chronic form of inflammatory bowel disease characterized by inflammation of the lining of the colon. Symptoms of active ulcerative colitis include rectal bleeding, abdominal pain, increased stool frequency, loss of appetite, fever and weight loss.
IPSCIO Record ID: 239024
Licensor possesses significant expertise in the field of antiinflammatory therapeutics, and dersalazine represents the culmination of years of internal research.
Dersalazine is a new chemical entity that combines a well-known anti-inflammatory agent, 5-ASA, with a novel potent agent that acts as a PAF antagonist and an inhibitor of key interleukin cytokines to achieve a synergistic therapeutic effect when compared to the activities of each component separately. Chemical cleavage of dersalazine by colonic bacteria releases the two active compounds for the topical treatment of inflammation in the colon. The 5-ASA molecule contained in dersalazine has known antioxidant properties which may ameliorate the deleterious inflammatory effects ascribed to the overproduction of free radicals.
IPSCIO Record ID: 29002
IPSCIO Record ID: 266736
Licensor grants to the extent of the Licensed Territory a nonexclusive license to use the Licensed Technology as necessary to exploit all rights granted with respect to the patent rights in the Licensed Field, with the right to sublicense.
Rifaximin means rifaximin, any pharmaceutical equivalents, salts and derivatives thereof.